We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Notice is hereby given that a class action lawsuit was filed in the United States
District Court for the District of New Jersey against Bradley Pharmaceuticals
Inc. on behalf of purchasers of Bradley securities between Oct. 8, 2003 and
Feb. 25, 2005, inclusive.
Medicis Pharmaceutical Corp. agreed to buy Inamed
Corp., the company seeking to return silicone-gel breast implants to the U.S.
market for the first time in more than a decade, for $2.8 billion in stock and
cash. Inamed investors will get 1.4205 shares of Medicis, a Scottsdale, Ariz.-based
maker of skin treatments, and $30 in cash for each share they own, the companies
said in a Business Wire statement today.
The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC)
has issued AstraZeneca its second untitled letter in four months regarding promotional
activities for the company's cholesterol-lowering drug Crestor.
The U.S. economy operates in a complex global
environment that for the first time has seen the emergence of low-cost, high-value
innovators worldwide -- a situation that could affect the U.S. pharmaceutical
industry's pre-eminence in research and innovation, experts say.
The number of adverse event reports submitted to the FDA's Center for Drug Evaluation
and Research (CDER) increased nearly 14 percent in 2004, according to a preliminary
estimate from the agency.
German biotechnology company Brahms AG has reached a cooperation agreement with
a leading Japanese pharmaceuticals firm in the field of medical technology,
a top executive disclosed.
Cardiome Pharma announced that it entered into an agreement with a syndicate
of underwriters in connection with its previously announced public offering
of 8,500,000 common shares.